HC Wainwright Issues Positive Forecast for UTHR Earnings

Key Points

• HC Wainwright raised United Therapeutics’ Q3 2026 EPS forecast to $6.60 from $6.08 and projects $26.56 EPS for FY2026, with estimates rising to $55.98 by FY2030.
• United Therapeutics reported quarterly EPS of $7.27, beating the $6.86 consensus, while revenue of $783.3 million fell short of the $804.65 million estimate and declined 1.9% year over year.
• Analyst sentiment remains favorable, with 11 Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $646, compared with the stock’s reported $499.73 opening price.

United Therapeutics Corporation (NASDAQ:UTHR - Free Report) - Analysts at HC Wainwright raised their Q3 2026 earnings estimates for United Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $6.60 per share for the quarter, up from their prior estimate of $6.08. The consensus estimate for United Therapeutics' current full-year earnings is $26.33 per share. HC Wainwright also issued estimates for United Therapeutics' FY2026 earnings at $26.56 EPS, FY2027 earnings at $30.30 EPS, FY2029 earnings at $46.03 EPS and FY2030 earnings at $55.98 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business's quarterly revenue was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.41 earnings per share.

Several other research analysts also recently weighed in on the company. Weiss Ratings upgraded United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Bank of America lowered their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Finally, TD Cowen restated a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $646.00.

United Therapeutics Price Performance

UTHR opened at $499.73 on Monday. The business has a 50 day moving average price of $535.95 and a two-hundred day moving average price of $536.15. The company has a market cap of $21.43 billion, a PE ratio of 17.88, a P/E/G ratio of 1.69 and a beta of 0.59. United Therapeutics has a 52 week low of $302.19 and a 52 week high of $609.35.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Summit Street Capital Management LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth approximately $28,603,000. Freestone Grove Partners LP purchased a new position in United Therapeutics during the second quarter worth $654,000. Caisse de depot et placement du Quebec purchased a new position in United Therapeutics during the second quarter worth $154,304,000. Gallagher Fiduciary Advisors LLC acquired a new position in shares of United Therapeutics in the second quarter worth $307,000. Finally, Odyssean LLC acquired a new position in shares of United Therapeutics in the second quarter worth $2,950,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,648,140.36. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $565.98, for a total transaction of $5,376,810.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company's stock, valued at $22,929,547.74. This represents a 19.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 443,075 shares of company stock worth $241,508,744 in the last ninety days. 8.60% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source